PREVIEW
The emergence of bacterial resistance to the fluoroquinolones is threatening the therapeutic usefulness of this relatively new class of antimicrobial agents. Of particular concern is the unexpected emergence of resistance in Pseudomonas aeruginosa and in methicillin-resistant Staphylococcus aureus. Why is this phenomenon occurring so rapidly? Can it be slowed or reversed? Dr Stratton addresses these concerns and presents strategies for prescribing these valuable drugs.